CSL
Develops and delivers biotherapies and vaccines
Finance Transformation Lead - Fixed Term Contract Months
Three days in the office per working week are required in Speke, Liverpool.
About the job
- A bachelor's degree in Accounting, Finance, or a related discipline.
- At least 7 years of relevant experience in a multinational finance, shared services, transformation, or change delivery environment.
- Three to five years of demonstrated leadership experience leading teams, projects, or cross-functional workstreams.
- Experience delivering finance process transformation, operating model change, continuous improvement, or automation initiatives.
- Experience engaging senior stakeholders, influencing decisions, and communicating transformation impacts across diverse global teams.
- Experience with SAP and finance systems, including understanding of process design, controls, data flow, and system-enabled change.
- Proven ability to deliver complex initiatives to tight deadlines while maintaining strong governance, risk management, and stakeholder confidence.
- Lead finance transformation initiatives from concept through delivery, aligning scope, priorities, governance, and outcomes with Accounting Services and global finance strategy.
- Develop and maintain transformation roadmaps, delivery plans, milestones, risks, and dependencies across process, people, data, and technology workstreams.
- Drive global standardisation, simplification, and automation of close and accounting processes, ensuring solutions are scalable, controlled, and aligned with global policy.
- Partner with Financial Controllers, Technology, and business stakeholders to identify improvement opportunities, define future-state processes, and secure alignment on change impacts.
- Establish programme governance, including status reporting, decision forums, issue management, stakeholder engagement, and escalation routes.
- Lead change adoption activities so the Close Operations team understands new processes, roles, controls, and ways of working.
- Define and track transformation benefits, performance indicators, and control improvements to demonstrate measurable value and sustained outcomes.
- Support delivery of digital enablement, system enhancements, and data quality improvements that improve close efficiency, visibility, and decision-making.
- Provide leadership to eight direct reports through coaching, prioritisation, resource planning, and performance management.
- Lead coordination and delivery of external and internal audit requests.
- An MBA or other advanced degree in a related field.
- Professional certification such as ACA, ACCA, or CIMA.
- Experience in a global scientific or pharmaceutical industry or shared service environment.
About the company
CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Parkville, Australia
Founded
1916
Get referred to CSL
See people who can refer or advise you
Simplify's Take
What believers are saying
- CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
- US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
- VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.
What critics are saying
- FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
- CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
- The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.
What makes CSL unique
- CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
- Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
- HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...
CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.
Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.
CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.
Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.